The subject of the present invention is a whole-cell catalysis process for converting substrates of cytochrome P450 monooxygenases of eukaryotic origin into valuable biotechnological products. The subject of the present invention is also microorganisms genetically engineered to achieve those biotransformations with high rates and processes to prepare these microorganism strains.

The present invention relates to methods and compositions for treating and/or preventing allergic diseases or conditions by inhibiting one or more components of the steroidogenic pathway.

Hybrid proteins with cytochrome P450 activity and which are encapsulated in a nanocapsid (nanoparticles charged with cytochrome P450 activity) are designed and synthesized, these hybrid proteins being immunologically inert and recognized by breast cancer cells.

The present invention relates to methods and compositions for treating and/or preventing allergic diseases or conditions by inhibiting one or more components of the steroidogenic pathway.

The present invention relates to novel process for the production of ketoisophorone via biocatalytic conversion of isophorone, in particular a one-pot biocatalytic system for conversion of ?-isophorone in a two-step oxidation process, with a first oxidation being catalyzed by a heme containing oxidoreductase such as a cytochrome P450 monooxygenase followed by another oxidation which can be either a chemical reaction or a biocatalytic reaction, in particular wherein the oxidation is catalyzed by an NAD(P) or NADP(H)-dependent oxidoreductase. The invention further provides polypeptides and nucleic acid sequences coding for cytochrome P450 monooxygenase with modified (higher) substrate selectivity, total turnover numbers and/or (re)activity compared to the wild-type enzyme. Ketoisophorone is useful as building block in the synthesis of vitamins and carotenoids.

The present invention relates to methods and compositions for treating and/or preventing allergic diseases or conditions by inhibiting one or more components of the steroidogenic pathway.

Described herein are the nucleic acid and the amino acid sequences of a cytochrome P450 capable of oxidizing terpene molecules. Also described herein are methods of oxidizing terpene molecules including contacting the cytochrome P450 with the terpene molecule intended to be oxidized. In particular, the method may be carried out in vitro or in vivo to produce oxidized terpene molecules, which may be used in different technical fields such as for example perfumery and flavoring. Also described herein is an expression vector containing the nucleic acid. A non-human host organism or a cell transformed with the nucleic acid is also an object of the disclosure.

The present invention relates to methods and compositions for treating and/or preventing allergic diseases or conditions by inhibiting one or more components of the steroidogenic pathway.

Described herein are the nucleic acid and the amino acid sequences of a cytochrome P450 capable of oxidizing terpene molecules. Also described herein are methods of oxidizing terpene molecules including contacting the cytochrome P450 with the terpene molecule intended to be oxidized. In particular, the method may be carried out in vitro or in vivo to produce oxidized terpene molecules, which may be used in different technical fields such as for example perfumery and flavoring. Also described herein is an expression vector containing the nucleic acid. A non-human host organism or a cell transformed with the nucleic acid is also an object of the disclosure.

The present invention relates to a fusion protein, to a nucleic acid coding for the protein, to a vector comprising the nucleic acid, to a host cell comprising the nucleic acid and/or vector, to a process for producing a fusion protein and to a process for bioconverting a substrate. The fusion protein of the present invention successively comprises (i) at least one polypeptide for targeting, and anchoring to, the bacterial membrane, (ii) at least one polypeptide corresponding to the hydrophilic domain of a plant P450 cytochrome, (iii) at least one binding polypeptide comprising at least 47 amino acids, and (iv) at least one polypeptide corresponding to the hydrophilic domain of a plant NADPH-dependent cytochrome P450 reductase.